Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital Universitari, Barcelona, and Universitat Autonoma de Barcelona, Bellaterra, Spain.
JAMA Neurol. 2023 Jun 1;80(6):605-613. doi: 10.1001/jamaneurol.2023.0611.
Acute symptomatic seizures occurring within 7 days after ischemic stroke may be associated with an increased mortality and risk of epilepsy. It is unknown whether the type of acute symptomatic seizure influences this risk.
To compare mortality and risk of epilepsy following different types of acute symptomatic seizures.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed data acquired from 2002 to 2019 from 9 tertiary referral centers. The derivation cohort included adults from 7 cohorts and 2 case-control studies with neuroimaging-confirmed ischemic stroke and without a history of seizures. Replication in 3 separate cohorts included adults with acute symptomatic status epilepticus after neuroimaging-confirmed ischemic stroke. The final data analysis was performed in July 2022.
Type of acute symptomatic seizure.
All-cause mortality and epilepsy (at least 1 unprovoked seizure presenting >7 days after stroke).
A total of 4552 adults were included in the derivation cohort (2547 male participants [56%]; 2005 female [44%]; median age, 73 years [IQR, 62-81]). Acute symptomatic seizures occurred in 226 individuals (5%), of whom 8 (0.2%) presented with status epilepticus. In patients with acute symptomatic status epilepticus, 10-year mortality was 79% compared with 30% in those with short acute symptomatic seizures and 11% in those without seizures. The 10-year risk of epilepsy in stroke survivors with acute symptomatic status epilepticus was 81%, compared with 40% in survivors with short acute symptomatic seizures and 13% in survivors without seizures. In a replication cohort of 39 individuals with acute symptomatic status epilepticus after ischemic stroke (24 female; median age, 78 years), the 10-year risk of mortality and epilepsy was 76% and 88%, respectively. We updated a previously described prognostic model (SeLECT 2.0) with the type of acute symptomatic seizures as a covariate. SeLECT 2.0 successfully captured cases at high risk of poststroke epilepsy.
In this study, individuals with stroke and acute symptomatic seizures presenting as status epilepticus had a higher mortality and risk of epilepsy compared with those with short acute symptomatic seizures or no seizures. The SeLECT 2.0 prognostic model adequately reflected the risk of epilepsy in high-risk cases and may inform decisions on the continuation of antiseizure medication treatment and the methods and frequency of follow-up.
缺血性中风后 7 天内发生的急性症状性癫痫发作可能与死亡率增加和癫痫风险增加有关。目前尚不清楚急性症状性癫痫发作的类型是否会影响这种风险。
比较不同类型的急性症状性癫痫发作后的死亡率和癫痫风险。
设计、地点和参与者:这项队列研究分析了 2002 年至 2019 年来自 9 个三级转诊中心的数据。推导队列纳入了来自 7 个队列和 2 个病例对照研究的神经影像学证实的缺血性中风且无癫痫发作史的成年人。在神经影像学证实的缺血性中风后发生急性症状性全面性癫痫发作的 3 个独立队列中进行了复制。最终数据分析于 2022 年 7 月进行。
急性症状性癫痫发作的类型。
全因死亡率和癫痫(中风后至少 1 次无诱因发作>7 天)。
共纳入 4552 名成年人进行推导队列(2547 名男性参与者[56%];2005 名女性[44%];中位年龄为 73 岁[IQR,62-81])。急性症状性癫痫发作发生在 226 名患者中(5%),其中 8 名(0.2%)出现癫痫持续状态。在急性症状性癫痫持续状态患者中,10 年死亡率为 79%,而急性症状性短时间发作患者为 30%,无癫痫发作患者为 11%。急性症状性癫痫持续状态后中风幸存者 10 年癫痫风险为 81%,而急性症状性短时间发作幸存者为 40%,无癫痫发作幸存者为 13%。在 39 名缺血性中风后发生急性症状性癫痫持续状态的复制队列中(24 名女性;中位年龄为 78 岁),10 年死亡率和癫痫风险分别为 76%和 88%。我们使用急性症状性癫痫发作类型作为协变量更新了以前描述的预后模型(SELECT 2.0)。SELECT 2.0 成功捕获了具有高发性中风后癫痫风险的病例。
在这项研究中,与急性症状性短时间发作或无发作的患者相比,伴有癫痫持续状态的中风和急性症状性癫痫发作的患者死亡率和癫痫风险更高。SELECT 2.0 预后模型充分反映了高危病例的癫痫风险,并可能为继续抗癫痫药物治疗的决策以及随访的方法和频率提供信息。